Key result
CGRP increases adenylate cyclase activity ~100% in human kidney medullo-papillary tissue where calcitonin is inactive.
CGRP stimulates adenylate cyclase activity in the medullo-papillary portion of the human kidney through a calcitonin-independent mechanism.
CGRP may modulate human renal medullary signaling; hypothesis-generating for kidney physiology and requires in vivo validation.
Calcitonin (CT) gene-related peptide (CGRP)-like immunoreactivity was detected in both the cortex and medullo-papillary portion of human kidneys. The two forms of human CGRP as well as rat CGRP were capable of stimulating renal cortical adenylate cyclase activity in a concentration-related manner, with a half-maximally effective concentration (EC50) similar to that of human CT and approximately 100-1000 times higher than that of salmon CT. However, in the medullo-papillary portion, in which both salmon CT and human CT were inactive, the two forms of human and rat CGRP increased adenylate cyclase activity by 100%, with EC50 values ranging from 36 nmol/L to 1 mumol/L. In cortical membrane preparations the effect of CGRP was additive to that of salmon CT. We concluded that regional differences exist in the effect of CT and CGRP in human renal tissue and that in the medullo-papillary portion and possibly in the cortex, CGRP stimulates adenylate cyclase activity through a CT-independent mechanism.
No takes yet. Share an insight, caveat, or question.
Geppetti et al. (1989) studied this question. Calcitonin gene-related peptide (CGRP) vs. Calcitonin (CT) was evaluated on Adenylate cyclase activity stimulation. Calcitonin gene-related peptide (CGRP) increased adenylate cyclase activity by 100% in the medullo-papillary portion of human kidneys, where calcitonin was inactive.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: